It has been shown that the expression and activity of NHE-1 were increased in cells resistant to doxorubicin and that inhibition of NHE-1 by a pharmacological inhibitor restores sensitivity to this anti-cancer agent [152]. Here, SLC9A1 is linked to cancer.